Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
Daniel AlcoleaMichal Schnaider BeeriJulio C RojasRaquel C GardnerAlberto LleóPublished in: Neurology (2023)
Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases. Currently, research studies have reported robust assays of blood markers for the detection of amyloid and tau pathologies specific to Alzheimer's disease (Aß peptides, p-tau), as well as non-specific blood markers of neuronal (neurofilament light, ß-synuclein, ubiquitin-C-terminal-hydrolase-L1) and glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiological processes in several neurodegenerative diseases. In the near future, these markers may be used for screening, diagnosis or disease and treatment response monitoring. Blood-based biomarkers for neurodegenerative diseases have been rapidly implemented in research, and they have the potential to enter clinical use soon in different clinical settings. In this review, we will describe the main developments and their potential implications for the general neurologist.